Cargando…

Efficacy of Percutaneous Sclerotherapy in Low Flow Venous Malformations - A Single Center Series

PURPOSE: We analyzed results of percutaneous sclerotherapy for venous malformations (VMs) in head, neck and extremities. MATERIALS AND METHODS: Thirty-five patients with head and neck and extremities VM treated by sclerotherapy with bleomycin and sodium tetradecyl sulphate (STS) were retrospectively...

Descripción completa

Detalles Bibliográficos
Autor principal: Ahmad, Saima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Interventional Neuroradiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433194/
https://www.ncbi.nlm.nih.gov/pubmed/30827065
http://dx.doi.org/10.5469/neuroint.2019.00024
_version_ 1783406256841555968
author Ahmad, Saima
author_facet Ahmad, Saima
author_sort Ahmad, Saima
collection PubMed
description PURPOSE: We analyzed results of percutaneous sclerotherapy for venous malformations (VMs) in head, neck and extremities. MATERIALS AND METHODS: Thirty-five patients with head and neck and extremities VM treated by sclerotherapy with bleomycin and sodium tetradecyl sulphate (STS) were retrospectively reviewed. A pre-treatment magnetic resonance imaging was done for all patients to diagnose the lesion. Each lesion received 1 to 11 sessions (average, 2.7; standard deviation [SD], 2.03). We evaluated percentage reduction in swelling size and a Likert scale review of subjective feelings of the patients. RESULTS: Sixteen had a complete obliteration; by sclerotherapy alone (n=13) and surgery after a 75% reduction (n=3). Ten patients had a significant reduction up to 75% and three patients by 50%. Four had a minimal decrease with reduction of 25% or less. Follow-up duration of the patients varied from a minimum of 6 months up to 3 years (average, 15.7 months; SD, 7.8 months). Of all patients, three refused further treatment and were lost to follow-up, while another two were referred to a dermatologist. Thirteen patients reported feeling excellent after the sessions. Eight patients claimed to feel slightly better compared to before the sessions started. Only three patients complained of feeling the same before and after the sessions. None of the patients still in follow-up have reported a recurrence of a lesion thus far. CONCLUSION: Sclerotherapy using bleomycin and STS as sclerosants is a safe and effective primary treatment for VMs in the head and neck as well as in extremities.
format Online
Article
Text
id pubmed-6433194
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Society of Interventional Neuroradiology
record_format MEDLINE/PubMed
spelling pubmed-64331942019-04-02 Efficacy of Percutaneous Sclerotherapy in Low Flow Venous Malformations - A Single Center Series Ahmad, Saima Neurointervention Original Paper PURPOSE: We analyzed results of percutaneous sclerotherapy for venous malformations (VMs) in head, neck and extremities. MATERIALS AND METHODS: Thirty-five patients with head and neck and extremities VM treated by sclerotherapy with bleomycin and sodium tetradecyl sulphate (STS) were retrospectively reviewed. A pre-treatment magnetic resonance imaging was done for all patients to diagnose the lesion. Each lesion received 1 to 11 sessions (average, 2.7; standard deviation [SD], 2.03). We evaluated percentage reduction in swelling size and a Likert scale review of subjective feelings of the patients. RESULTS: Sixteen had a complete obliteration; by sclerotherapy alone (n=13) and surgery after a 75% reduction (n=3). Ten patients had a significant reduction up to 75% and three patients by 50%. Four had a minimal decrease with reduction of 25% or less. Follow-up duration of the patients varied from a minimum of 6 months up to 3 years (average, 15.7 months; SD, 7.8 months). Of all patients, three refused further treatment and were lost to follow-up, while another two were referred to a dermatologist. Thirteen patients reported feeling excellent after the sessions. Eight patients claimed to feel slightly better compared to before the sessions started. Only three patients complained of feeling the same before and after the sessions. None of the patients still in follow-up have reported a recurrence of a lesion thus far. CONCLUSION: Sclerotherapy using bleomycin and STS as sclerosants is a safe and effective primary treatment for VMs in the head and neck as well as in extremities. Korean Society of Interventional Neuroradiology 2019-03 2019-02-28 /pmc/articles/PMC6433194/ /pubmed/30827065 http://dx.doi.org/10.5469/neuroint.2019.00024 Text en Copyright © 2019 Korean Society of Interventional Neuroradiology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Ahmad, Saima
Efficacy of Percutaneous Sclerotherapy in Low Flow Venous Malformations - A Single Center Series
title Efficacy of Percutaneous Sclerotherapy in Low Flow Venous Malformations - A Single Center Series
title_full Efficacy of Percutaneous Sclerotherapy in Low Flow Venous Malformations - A Single Center Series
title_fullStr Efficacy of Percutaneous Sclerotherapy in Low Flow Venous Malformations - A Single Center Series
title_full_unstemmed Efficacy of Percutaneous Sclerotherapy in Low Flow Venous Malformations - A Single Center Series
title_short Efficacy of Percutaneous Sclerotherapy in Low Flow Venous Malformations - A Single Center Series
title_sort efficacy of percutaneous sclerotherapy in low flow venous malformations - a single center series
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433194/
https://www.ncbi.nlm.nih.gov/pubmed/30827065
http://dx.doi.org/10.5469/neuroint.2019.00024
work_keys_str_mv AT ahmadsaima efficacyofpercutaneoussclerotherapyinlowflowvenousmalformationsasinglecenterseries